

PRESS RELEASE



ExonHit raises EUR 1.45 million through the exercise of warrants

Paris, France – July 8, 2009 – ExonHit Therapeutics S.A. (Alternext: ALEHT) today announced the final results of the fund raising transaction by exercise of warrants issued and awarded freely to its shareholders on December 24, 2008 (the “warrants 08/09”).

Ten warrants 08/09 gave their holders the right to subscribe for one new share at EUR 3.50 on or before June 30, 2009. Over the warrant exercise period, i.e., from December 24, 2008 through June 30, 2009, out of a total of 26,877,950 warrants issued, 4,143,840 warrants 08/09 have been exercised. The warrants 08/09 which had not been exercised by June 30, 2009 have been cancelled.

“These additional funds will further strengthen our cash position and contribute to the financing of our development programs,” stated Dr. Loïc Maurel, President of the Management Board of ExonHit Therapeutics.

ExonHit Therapeutics raised EUR 1,450,344 through the exercise of the warrants 08/09 leading to the issue of 414,384 new shares. This amount will contribute to ExonHit’s cash position which corresponds to 24 months of activity.

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast emerging healthcare player active in both therapeutics and diagnostics. The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative blood based diagnostic tests and therapeutics for neurodegenerative and cancer indications. ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with bioMérieux and Allergan.

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

ExonHit Therapeutics

Media Contact

Corinne Hoff

+33 1 58 05 47 04

corinne.hoff@exonhit.com

Investor Contact

Loïc Maurel

+33 1 53 94 77 00

loic.maurel@exonhit.com